NCT05266495View on ClinicalTrials.gov

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

March 13, 2023

Study Completion Date

March 13, 2023

Conditions
Neovascular Age-related Macular Degeneration
Interventions
OTHER

Brolucizumab

There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.

Trial Locations (1)

112412

Novartis Investigative Site, Abu Dhabi

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY